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1. Introduction 
1.1 Skin 
Skin is composed of three layers: epidermis, dermis and hypodermis (Sugihara et al., 1991). 
Epidermis is divided into five layers namely, stratum basale, spinosum, granulosum, lucidum, 
and corneum (Bragulla & Homberger, 2009, Nagarajan et al., 2009). The differentiation 
process implies that keratinocytes are transformed through the different cell layers to reach 
their complete maturation in the stratum corneum (Harding, 2004). In this process, various 
proliferation and differentiation markers are expressed in a well-orchestrated sequence of 
events (Fig. 1). When the differentiation process is negatively affected, skin pathologies such 
as psoriasis can appear (Rashmi et al., 2009, Karlsson et al., 2004). 
 
Fig. 1. Differentiation process 
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1.2 Psoriasis 
1.2.1 Prevalence 
Psoriasis is a severe skin disease affecting men and women worldwide. It affects about 2 % 
of the world population (Baker et al., 2008, Wippel-Slupetzky & Stingl, 2009). Previous 
studies have demonstrated that psoriasis prevalence varies as a result of two factors: (1) 
geographical localization and (2) ethnic group. Firstly, psoriasis shows a significant 
geographical variability with the lowest incidence seen at the equator and increasing 
frequency towards the poles (Kormeili et al., 2004, Krueger & Bowcock, 2005, Lowes et 
al., 2007) (Fig. 2). Secondly, even if psoriasis is universal, it does not affect all ethnic 
groups in a similar way. In fact, various studies have demonstrated that psoriasis 
prevalence can be modified in function of ethnic factors. They established that, in the 
United States, the prevalence was of 0.5 to 0.7 % in African population compared with 
1.4 to 4.6 % for Caucasian population (Schon & Boehncke, 2005). Furthermore, some 
populations, such as Samoan population (Polynesia), are exempt from psoriasis, whereas 
other ethnic groups show a high percentage of affected peoples such as observed in 
Kazach’ye population (12.0 %).  
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Fig. 2. Worldwide psoriasis prevalence 
Psoriasis prevalence shows a significant geographical variability. A lower incidence can be 
observed at the equator while the frequency increases towards the poles. Studies suggest 
that the incidence may be related with the time and/or the intensity exposure to the 
ultraviolet wavelengths of sunlight (Menter & Stoff, 2010). 
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1.2.2 Physiopathology 
Psoriatic skin is characterized by remarkable hyperplasia of the epidermis (acanthosis), loss 
of the granular layer, increased vascularization in the dermis, and thickening of the 
cornified layer (hyperkeratosis). Additionally, the incomplete keratinocyte differentiation 
(parakeratosis) and the leukocyte infiltration in skin are hallmarks of this disease (Tonel & 
Conrad, 2009).   
So far, the pathogenesis of psoriasis constitutes a matter of scientific debate. Controversy 
exists about whether this disease starts as a primary abnormality of altered keratinocytes or 
as a result of an altered immune response against an undetermined antigen. According to 
the first hypothesis, epidermal alterations could be sufficient for the initiation of psoriasis in 
genetically predisposed individuals. Moreover, it has been demonstrated that the 
abrogation of JunB/activator protein (AP-1) in epidermal mouse keratinocytes leads to a 
phenotype that notably mimics psoriasis with inflammation, disturbances in epidermal 
differentiation and dermal changes, including the expression of chemokines/cytokines, 
which are able to recruit neutrophils and macrophages in the epidermis (Zenz et al., 2005). 
According to the second hypothesis, psoriasis could be a result of an altered immune 
response to an undetermined antigen. However, it is still not clear where the psoriatic 
immune response begins. This theory arises from evidences obtained using xenograft 
psoriatic models, where uninvolved psoriatic skin is transformed into a psoriatic lesion 
under the action of skin resident cells present in the graft (Boyman et al., 2004, Conrad et al., 
2007). The failure to generate a psoriatic lesion after the administration of an anti-CD3 mAb, 
demonstrated that T cells and not keratinocytes alone were necessary to generate the 
psoriatic phenotype (Boyman et al., 2004, Conrad et al., 2007). Thus, psoriatic lesions could 
be initiated by an initial trigger which activates dendritic cells (DCs) and induces their 
migration to skin-draining lymph nodes. DCs thus prime antigen-specific T cells to 
differentiate into effector T cells bearing the skin addressing CLA (Cutaneous Lymphocyte 
Antigen). Activated T cells then traffic to the skin, where they induce together with DCs and 
other cells, the release pro-inflammatory cytokines, which in turn stimulate keratinocytes to 
synthesize other cytokines, chemokines and pro-inflammatory molecules, thereby causing 
the typical epidermal changes observed in psoriasis (Bowcock & Krueger, 2005). 
Furthermore, migration of T cells in the epidermis seems to be connected with the 
disturbances of desmosome connection between keratinocytes, thereby contributing to the 
disruption of epidermal integrity (Krueger, 2002). That could be interpreted by 
keratinocytes as an injury with a further wound repair response, and the release of cytokines 
leading to a regenerative epidermal growth.  
Psoriasis is considered to be an immune-mediated disease characterized by a predominantly 
Th1-type cytokine profile in lesional skin with elevated levels of interferon-┛ (INF-┛), 
tumour necrosis factor-alpha (TNF-┙), IL-12, and IL-18, among others. Thus, the secretion of 
the INF-┙ from DCs and the production of TNF-┙ by cells of the innate and adaptive 
immune system are considered to be one of the earliest events leading to psoriasis (Nestle et 
al., 2005). Cytokines released by T cells, DCs, macrophages and neutrophils such as IL-1, IL-
6 and INF-┛ have been shown to directly induce epidermal hyperplasia (Krueger, 2002). 
Additionally, other inflammatory cytokines such as IL-23, have gained attention for their 
role in psoriasis pathogenesis. IL-23 leads to the production of IL-17 and IL-22, contributing 
to the enhancement and maintenance of inflammation as well as epidermal proliferation 
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(Chan et al., 2006, Wolk et al., 2004). Intradermal injection of this IL-23 contributes to the 
development of epidermal acanthosis in mice (Chan et al., 2006, Zheng et al., 2007). Other 
evidence supporting its role in psoriasis includes the clinical efficacy of anti-p40 monoclonal 
antibody (Krueger et al., 2007).  
Overall, psoriasis involves a complex interplay between various cells of the immune system 
and skin, including dendritic cells, T cells, neutrophils, and keratinocytes, which leads to the 
release of numerous cytokines and chemokines that signal keratinocytes to hyperproliferate 
and undergo abnormal differentiation (Gottlieb et al., 2003).   
1.2.3 Treatment satisfaction: Results of worldwide surveys 
Previous worldwide surveys of psoriasis affected individuals have revealed widespread 
dissatisfaction with available treatments, as well as frustration with current management 
strategies, thereby demonstrating the need for more appropriate forms of therapy (Nijsten et 
al., 2005, Stern et al., 2004) and the importance for an improved access for patients to health 
care services (Klotz et al., 2005, Simpson et al., 2006). 
In 1998, a self-administered questionnaire was mailed to the entire membership of the 
National Psoriasis Foundation in the United States (n=40,350) and followed by a telephone 
survey of patients with severe psoriasis. Of the 40,350 questionnaires mailed out, a response 
rate of 43 % was realized. Although 48 % of responders were very or fairly satisfied with 
psoriasis treatments, a nearly similar number of patients (49 %) reported that they were only 
somewhat or not at all satisfied (Krueger et al., 2001). Additionally, 46 % of patients 
responded that their treatment functioned “just somewhat well” or “not well at all” and a 
high degree of dissatisfaction with the capacity of treatments to control the symptoms was 
reported. In the case of patients with severe disease, 78 % reported that their treatment did 
not function well enough, thereby leading them to a frustration with their medications 
(Krueger et al., 2001). In fact, 32 % of these patients replied that the treatment they received 
was not aggressive enough. As a consequence, many of the responders (43 %) had tried 
over-the-counter medications or alternative therapies such as herbs, relaxation or 
acupuncture in order to control their psoriasis (Krueger et al., 2001). Another survey, 
conducted with 77 psoriatic patients in Israel also demonstrated that 62 % of patients used 
complementary and alternative medicines including herbal medicines and nutritional 
treatments followed by homeopathy and traditional Chinese medicine. The main reasons for 
complementary and alternative medicines were: the less toxic indications, disappointment 
with conventional treatments and stress reduction (Ben-Arye et al., 2003).    
In order to assess the satisfaction of psoriatic patients with four systemic medications 
(methotrexate, PUVA-therapy, cyclosporin and acitretin), 1,197 patients were interviewed in 
the United States between 2001 and 2002 (Nijsten et al., 2005). Of these patients, only 26 % 
(n=311) indicated the use of these systemic treatments for their psoriasis. Less than 40 % of 
these patients were very satisfied with their treatment, while a comparable proportion 
indicated being dissatisfied. Low levels of satisfaction were related with treatment 
resistance, toxicity, convenience, costs and unrealistic patients’ expectations (Nijsten et al., 
2005). Patients were more satisfied with methotrexate and PUVA-therapy than with acitretin 
and cyclosporine. Furthermore, PUVA-therapy had the highest satisfaction rate and 
cyclosporine the lowest compared with other therapies.   
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In 2002, the European Federation of Psoriasis Patient Associations (EUROPSO) carried out a 
Europe-wide survey investigating quality of life of psoriatic patients, as well as their 
satisfaction with available treatments (Dubertret et al., 2006). Self-administered 
questionnaires were thus mailed to members of psoriasis associations in Germany, Belgium, 
Finland, France, Czech Republic, Italy and Netherlands. From 18,386 responders, 17,990 had 
psoriasis. At the time of the survey, 32 % of all participants used a topical treatment, 17 % a 
systemic treatment and 13 % phototherapy treatment. Although many patients were 
satisfied with the information and care offered by their physicians (40 % highly satisfied), 
available treatment modalities were less satisfactory, with over 70 % reporting low or 
moderate satisfaction. Higher satisfaction (score of 8–10) was observed for treatments with 
methotrexate (30 %), cyclosporin (28 %) and fumarates (26 %) followed by PUVA-therapy 
(38 %). Lower satisfaction (score of 1–4) was observed for tazarotene (42 %) and etretinate 
(38 %).  Responders (50 %) reported that the time consumed during therapies was the most 
troublesome aspect, followed by ineffectiveness of treatments (32 %). Patients with severe 
psoriasis reported side effects as a problem (31 %), whereas only 23 % of patients with mild 
psoriasis considered this aspect (Dubertret et al., 2006). Furthermore, another survey 
conducted in 2003 with 301 psoriatic patients in Europe, also demonstrated that 42 % of 
patients were dissatisfied with their treatment (Christophers et al., 2006). Lack of satisfaction 
was lower among the patients receiving treatment with more than one agent, and in those 
who had more frequent psoriasis relapses, demonstrating the high need for safe and 
effective therapies for management of this disease (Christophers et al., 2006).  
Patients diagnosed with psoriasis in the United States between 2006 and 2007 were 
contacted to complete an online survey ("Psoriasis Patient Study Wave 1") related to their 
psoriasis diagnosis, treatment and treatment satisfaction (total of patients=1,006). Of those 
who had ever taken a prescription (topical, phototherapy, systemic oral or biologics, n=557), 
31.8 % (n=177) reported that their current treatment was not able to satisfactorily clear their 
psoriasis. When patients were separated by treatment, 20.8 % (n=33) of those using 
biologics, 31.1 % (n=33) of those using systemic oral, 46.4 % (n=13) of those using 
phototherapy, and 34.2 % (n=163) of those using topical treatments reported that their 
current treatment was not able to satisfactorily clear their psoriasis. Patients with severe 
disease were less satisfied than those with mild and moderate disease (47.9 % vs. 32.9 % vs. 
27.6 % respectively) (DiBonaventura et al., 2010). 
An online Canadian survey conducted in December 2007 with 514 patients diagnosed with 
moderate, severe and very severe plaque psoriasis demonstrated that awareness of available 
treatment options ranged from 98 % for topical treatments to 75 % for phototherapies, 49 % 
for oral treatments and 35 % for injectable medications. Satisfaction with treatments were 
generally low, and only 24 % of patients reported to be “very satisfied” with their current 
therapy. Satisfaction decreased with the increase of psoriasis severity, 39 % of patients with 
mild/very mild psoriasis reported to be ‘‘very satisfied’’, compared with 16 % of those 
diagnosed with moderate/severe/very severe psoriasis (Wasel et al., 2009). In this survey, 
dissatisfaction with the efficacy of antipsoriatic treatment was highlighted by the majority of 
patients (68 %) reporting that ‘‘No medication works really well for my psoriasis’’. 
Additionally, patients with severe psoriasis more frequently complained that “medication 
was very ineffective for my psoriasis” compared to those less affected (49 %, 69 % and 77 % 
for respondents with 0–2 %, > 3%, and > 10% of body surface area (BSA) involvement, 
respectively) (Wasel et al., 2009). Additionally, most affected patients were concerned about 
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side effects from medication to treat psoriasis (54 %, 64 % and 69 % of psoriatic patients with 
0–2 %, > 3% and > 10% BSA involvement, respectively). Patients also manifested that the 
reasons for treatment discontinuation were as following: lack of efficacy (60 %), 
inconvenience (23 %) and improvement of symptoms (22 %), side effects (20 %), cost (14 %) 
and doctor’s advice (14 %) (Poulin et al., 2010).  
Overall, results of worldwide surveys demonstrate that a substantial proportion of psoriatic 
patients are highly dissatisfied with current therapies, particularly those with greater 
psoriasis severity. A perceived lack of efficacy of available treatments suggests the 
importance of the development of more relevant treatments, in order to allow the 
establishment of more individualized therapies.   
2. Challenges for antipsoriatic drug development 
The most significant challenge for antipsoriatic drug development is to provide safe and 
effective long-term management of this disease. In general, a conventional vision of this 
process starts with the study of disease in relevant model systems, in order to determine 
cellular and molecular mechanisms involved in pathogenesis. Afterwards, new therapeutic 
approaches are developed in these models before clinical trials in humans (Guttman-Yassky & 
Krueger, 2007). The comprehension that psoriasis is an immune-mediated disease, which 
involves a complex interplay of T cells, natural killer cells, dendritic cells, macrophages and 
other leukocytes, has led to the development of new biological treatments. The positive results 
obtained with these agents have expanded our understanding on psoriasis pathogenesis. 
However, many questions remain regarding psoriasis pathogenesis, and other medications 
should be developed to offer individualized treatments able to improve patient’s quality of 
life. Some of the challenges for this field include the improvement of efficacy and safety of new 
drugs, the solution of problems related to formulation/administration/costs of new agents, 
and the development of more relevant psoriatic skin models.  
2.1 Efficacy 
Many psoriatic patients are unresponsive to current therapies or have aggressive disease 
that is not addressed by current approaches. The determination of relevant biomarkers 
directly related to psoriasis pathogenesis to be targeted with effective treatments could 
allow quantitative assessment of treatment response (Rashmi et al., 2009).  
2.2 Safety 
The challenge of improving the safety of new antipsoriatic drugs is a very important aspect 
for long-term therapies, and can be overcome through the understanding of the toxicity 
mechanisms of new agents at early stages of drug development. Unfortunately, this is not 
always feasible during the drug development process, and the “safety question” should 
respond to what constitutes an acceptable risk. Thus, it is important to carefully analyse the 
risk/benefit rate of new antipsoriatic agents, mainly in the case of severe disease.  
2.3 Practical issues 
In the case of drugs approved for clinical use, their specific immunogenicity, costs, patient 
access and inconveniences for administration should be considerate. Other challenges 
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include the optimization of the new drug delivery to give maximum effects to its intended 
biological targets.   
2.4 Development of more relevant psoriatic skin models 
Maybe the most important challenge for antipsoriatic drug development is the inexistence of 
validated in vivo and in vitro skin models. Psoriasis is a complex disease in which 
interactions with 30 or more upregulated cytokines and chemokines implies the formation 
of interactive circuits that are not completely reproduced by in vivo and in vitro models. In 
the case of animal models, which are very important in pre-clinic stages of drug 
development, no one can fully mimic the genomic signature of this disease in which 
expression than more of 1,300 genes is altered (Guttman-Yassky & Krueger, 2007). Other 
problems are related to the fact that murine skin is different from human skin, and often 
the immune infiltrates are less intense and contain different mixtures of leucocytes 
compared with psoriatic plaques (Gudjonsson et al., 2007). Furthermore, animal models of 
epidermal hyperplasia are not selective enough, being also used for the study of other 
diseases, such as atopic dermatitis, even when different inflammatory genes are implied 
in these two diseases. Thus, it is not a surprise that targeted therapies such as the 
antibody efalizumab, are effective in both diseases (Farshidi & Sadeghi, 2006). The lack of 
representative in vivo and in vitro skin models could also be related to failures of clinical 
trials at late stages. Hence, some psoriatic models are of questionable value for the 
development of selective antipsoriatic treatments. A detailed explanation of these models 
will be provided in subsequent sections.   
3. In vivo and in vitro psoriatic skin models 
3.1 In vivo models 
3.1.1 Spontaneous mutations 
Psoriasis is a typical human skin disease. Even if spontaneous mutation models do not 
exhibit every features found in psoriasis, various pathology-like characteristics can be 
observed, including hyperkeratosis and scaly formation (Mizutani et al., 2003). Hundred of 
these spontaneous mutation models have been described in the literature (Sundberg et al., 
1990), but no one shows all the characteristics of psoriasis. However, these models can be 
really practical for studying individual characteristics such as hyperkeratosis (Schon, 2008). 
A comparison between the characteristics observed in the three major models of 
spontaneous mutations is presented in table 1. 
3.1.2 Xenotransplantation 
Animal models based on transgenic technology have been used extensively to study the 
pathogenesis of various skin diseases, including psoriasis (Raychaudhuri et al., 2001, Jean & 
Pouliot, 2010). Xenotransplantation approach consists of grafting a piece of in vivo psoriatic 
skin (or an in vitro psoriatic substitute) on a genetically modified mouse. Currently, three 
major models are used: athymic nude mice (Fraki et al., 1983), severe combined 
immunodeficient mice (SCID) (Raychaudhuri et al., 2001), and spontaneous AGR129 model 
(Boyman et al., 2004). The main difference between each model is the immunological 
potential of the immune system. Athymic nude mice have no thymus and therefore no T 
cells, whereas severe combined immunodeficient mice have no T and no B cells  
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Model Characteristics References 
Psoriasis-like Psoriasis-unlike
Homozygous asebia
(Scd1ab/Scd1ab) 
 
Epidermal acanthosis
 
Increased dermal 
vascularization 
 
Dermal infiltrate (mast 
cells and macrophages) 
Alterations of the 
cutaneous lipid 
metabolism different 
from psoriasis 
 
Lack of T cells and 
neutrophils 
 
(Schon, 
2008, Zheng 
et al., 1999) 
Flaky skin mice 
(Ttcfsn/Ttcfsn) 
 
Best spontaneous model 
of psoriasis described 
 
Proliferation and 
hyperkeratosis of 
stratified squamous 
epithelia  
 
Positive Koebner reaction 
after tape-stripping 
Comprises aspects not 
find in psoriasis 
  
Lack of the 
immunological side 
(Sundberg et 
al., 1990, 
Danilenko, 
2008, Stratis 
et al., 2006, 
Sundberg et 
al., 1994, 
Schon, 1999) 
  
Spontaneous chronic 
proliferative dermatitis 
mutation 
(Sharpincpdm/Sharpincpdm)
 
Hyperproliferative skin
 
Infiltration of 
inflammatory cells in the 
skin 
 
Dilation of blood vessels 
in the dermis 
Lack of T cells (Schon, 
1999) 
Table 1. Examples of spontaneous mutation models and their characteristics 
(Raychaudhuri et al., 2001). As for AGR129 model, it is characterized by the absence of T and 
B cells and by the presence of immature natural killer (NK) cells, less cytotoxic than mature 
NK cells (Boyman et al., 2004). A weaker system is potent to dwell skin transplants for a 
longer time on a compromised mouse upon rejection. Thus, the amount of transplant 
rejection is reduced in the AGR129 model compared to the others. Boyman et al. 
demonstrated that human uninvolved psoriatic skin grafted onto AGR129 mice 
spontaneously developed psoriatic plaques without the injection of any activated immune 
cells or any other exogenous factor, suggesting that uninvolved psoriatic skin is not exactly 
comparable to the normal human skin of healthy patients (Boyman et al., 2004, Gudjonsson 
et al., 2007, Jean & Pouliot, 2010). However, the absence of an inflammatory system could be 
a significant weakness of these models, since the importance of the immunology has been 
described by many research groups. 
3.1.3 Genetically modified models 
Development of rat and mouse transgenic models was an important step in the field of in 
vivo models. These genetically modified animals allow the observation of psoriasis-like 
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characteristics in rodents following the overexpression or underexpression of cytokines (or 
enzymes) (Bullard et al., 1996, Danilenko, 2008, Keith et al., 2005). It is important to note that 
psoriasis is a multisystemic skin disease, and that transgenic models consider only a single 
gene at the time. Thus, even if these models are interesting to observe isolated psoriasis-like 
features, they do not allow the study of all the characteristics of the pathology. There exist a 
broad variety of genetically modified in vivo models. An exhaustive list can be seen in table 
2 (Jean & Pouliot, 2010). 
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Targeting the immune system  
HLA-B27/┚2 microglobulin rat
+ + + + 
(Keith et al., 2005, 
Breban et al., 1996) 
Hypomorphic CD18
+ + + + 
(Bullard et al., 1996, 
Kess et al., 2003) 
E (CD103) + + ? + (Schon et al., 2000) 
K14/p40 + ? ? + (Kopp et al., 2001) 
 
Targeting vascular endothelium
pTek-tTA/Tie2 + + + + (Voskas et al., 2005) 
K14/VEGF + + + + (Xia et al., 2003) 
 
Targeting epidermal proteins
K5/Stat3C + + + + (Sano et al., 2005) 
IKK2 + + ? - (Pasparakis et al., 2002) 
c-Jun/JunB + + + + (Zenz et al., 2005) 
K14/KGF + + + - (Guo et al., 1993) 
K14/TGF- 
+ + ? 
Some 
animals
(Vassar & Fuchs, 1991) 
K14/IL-20 + + - - (Blumberg et al., 2001) 
K14/amphiregulin + + + + (Cook et al., 1997) 
K14/IL-1 + + - ? (Groves et al., 1995) 
K14/IL-6 + - - - (Turksen et al., 1992) 
K10/BMP-6 + + + + (Blessing et al., 1996) 
Involucrin/integrins + + + + (Carroll et al., 1995) 
Involucrin/MEK1 + + ? + (Hobbs et al., 2004) 
Involucrin/amphiregulin + + + + (Cook et al., 2004) 
Involucrin/IFN- + + + - (Carroll et al., 1997) 
Chymotryptic enzyme + + ? + (Hansson et al., 2002) 
Table 2. In vivo genetically modified models of psoriasis 
Reproduced and modified from Jean et al., 2010 according to the copyright policy of the 
publisher.  2010 InTech. 
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3.2 In vitro models  
3.2.1 Monolayer 
By using only a small skin biopsy, monolayer techniques allow the attainment of a large 
number of cells (normal or pathological) supporting the production of many experiments. In 
monolayer models, only one cell type is studied. Thus, keratinocytes (or fibroblasts) can be 
used to test different conditions or to observe psoriatic skin features such as 
hyperproliferation or abnormal differentiation of keratinocytes. These models allow the 
isolation of one cell type for step by step dissection of the implied mechanisms. Even if it 
was not possible to observe direct interaction between cell types, these models allowed the 
discovery of many interesting facts about psoriasis, and favoured a better understanding of 
the pathology (Jean & Pouliot, 2010). 
3.2.2 Collagen gels 
Despite the absence of a complete in vitro model allowing the observation of interactions 
between different cell types, such as keratinocytes and fibroblasts, some teams have 
developed specialized techniques which imply an exogenous matrix: the collagen gel. 
3.2.2.1 Organ culture 
Some teams decided to put down complete skin biopsies on collagen gel, containing 
fibroblasts, to observe cell proliferation. Total surface recovered by keratinocytes was used 
to calculate cell proliferation percentage (Saiag et al., 1985). Higher keratinocyte proliferation 
values were obtained in the presence of psoriatic fibroblasts (Saiag et al., 1985). Furthermore, 
this model led to the conclusion that normal fibroblasts are unable to suppress the 
hyperproliferative growth of psoriatic keratinocytes, and that hyperproliferation of normal 
epidermis can be induced both by uninvolved and involved psoriatic fibroblasts (Saiag et al., 
1985, Jean & Pouliot, 2010). 
3.2.2.2 Models using many cellular types 
Other teams developed skin substitutes composed of two cell types, in order to observe 
the effects of psoriatic keratinocytes on fibroblasts and vice versa. In a global way, these 
models consist of isolating normal and pathological cells from a small biopsy. Fibroblasts 
are extracted from dermis, expanded and seeded in collagen gel. Keratinocytes are 
extracted in a similar way and are placed on the pre-prepared collagen gel (Konstantinova 
et al., 1996). Barker et al. developed and characterized an in vitro psoriatic skin model 
using collagen gel. This model was very representative of the pathology (Barker et al., 
2004). In fact, they have demonstrated that the model kept many characteristics of 
psoriasis such as hyperproliferation and abnormal differentiation of keratinocytes, 
augmentation of the interleukin 6 and 8 concentrations, as well as the overexpression or 
underexpression of some proliferation, differentiation and inflammatory markers 
observed in psoriatic skin. Researchers concluded that involved and uninvolved skins 
seem to have the same pathological characteristics as psoriatic human skin (Barker et al., 
2004, Jean & Pouliot, 2010). Barker, Konstantinova and Saiag models are interesting in 
vitro models for studying psoriasis, but they are produced with a contractile exogenous 
material (collagen gel). 
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3.2.3 Self-assembly approach 
Facing the absence of exogenous material-free models, our group developed a new 
pathological skin model to study psoriasis in vitro by using the self-assembly approach 
(Michel et al., 1999) (Fig. 3). Briefly, normal and pathological fibroblasts are thawed and 
cultured with ascorbic acid for a period of time of four weeks. Then, dermal sheets are 
produced and removed from flasks. Two fibroblast sheets are superimposed to form a new 
dermal equivalent. Seven days later, normal or pathological keratinocytes are seeded on the 
dermal equivalent to obtain a new epidermal equivalent. After another 7 days of culture, the 
substitutes are raised to the air–liquid interface to favour cell differentiation and 
stratification. Finally, biopsies are taken after 21 days of culture at the air–liquid interface, 
and samples are analyzed using histological, immunohistochemical, physico-chemical or 
permeability techniques (Jean et al., 2009). 
Fig. 3. The self-assembly approach for the production of skin substitutes 
Schematic representation of the various steps of skin substitutes production in function of 
time. Reproduced and modified from Jean et al., 2010 according to the copyright policy of 
the publisher.  2010 InTech. 
In 2009, Jean et al. showed that self-assembled skin substitutes partially maintained 
psoriasis-like features such as a thick epidermis, hyperproliferation as well as abnormal cell 
differentiation of epidermal cells (Jean et al., 2009). In 2011, they demonstrated for the first 
time that pathological substitutes produced by the self-assembly approach can be treated 
with an anti-psoriatic molecule and react positively to the treatment such as observed in 
psoriatic skin in vivo. This functional study suggests that the self-assembled skin substitutes 
could be useful to better understand the mechanisms through which retinoic acid regulates 
cellular physiology in psoriatic skin, and could become an effective and innovative 
dermopharmaceutical tool for the screening of new treatments (Jean et al., 2011). 
4. Conclusion  
Psoriasis is characterized by the presence of physical and psychological pains, which can 
severely affect the quality of life of psoriatic patients. Currently, a broad spectrum of anti-
psoriatic treatments, both topical and systemic, is available for the management of psoriasis. 
These treatments only allow to control psoriasis without curing it. Challenges for 
antipsoriatic-drugs development are numerous, and the pharmaceutical industry strongly 
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needs highly predictive in vivo and in vitro models to improve the success rate of the 
development of new drugs. Effectively, the lack of representative in vivo and in vitro models 
could be related with failures of clinical trials. Thus, the elaboration of these models 
represents a key component in the fight against psoriasis.  
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